Status:
RECRUITING
Real-world Elecsys® GAAD Implementation and Validation to Improve Surveillance and Early Detection of HCC
Lead Sponsor:
Manchester University NHS Foundation Trust
Collaborating Sponsors:
University of Manchester
Roche Pharma AG
Conditions:
Liver Cirrhosis
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Patients with liver cirrhosis are at high risk of developing hepatocellular carcinoma (HCC) which implies significant mortality. At present current surveillance methods detect hepatocellular carcinoma...
Eligibility Criteria
Inclusion
- • Patients with known liver cirrhosis referred into or already under hepatocellular carcinoma surveillance
Exclusion
- Pregnancy/breast-feeding.
- Patients who do not have liver cirrhosis
- Patients who already have hepatocellular carcinoma
- Any patient who is unable to understand, retain and weigh information to make an informed decision, will be excluded from the study. The investigators will use every opportunity, including tele-interpretation services to minimise this from happening.
Key Trial Info
Start Date :
January 8 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2030
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT05971108
Start Date
January 8 2024
End Date
July 31 2030
Last Update
September 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Manchester University NHS Foundation Trust
Manchester, Greater Manchester, United Kingdom, M13 9WL